Clinical trial
ALIMTA (Pemetrexed) in Patients With Locally Advanced or Metastatic Cancer
NCT00034463 · Eli Lilly and Company, Industry · Completed
Key facts
| NCT number | NCT00034463 |
|---|---|
| Title | ALIMTA (Pemetrexed) in Patients With Locally Advanced or Metastatic Cancer |
| Official title | A Phase 1 Trial of ALIMTA (Pemetrexed) in Patients With Locally Advanced or Metastatic Cancer |
| Lead sponsor | Eli Lilly and Company, Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Metastases, Cancer |
| Intervention type | Drug |
| Interventions | ALIMTA, folic acid, multi-vitamins |
| First posted | Apr 30, 2002 |
| Last update posted | Jul 19, 2006 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: